AC Immune disclosed interim Phase II biomarker results for its active α‑synuclein vaccine that showed coherent changes across CSF and imaging markers, prompting the company to seek early regulator feedback. BioCentury reported elevated confidence in a possible disease‑modifying signal based on a suite of biomarkers including α‑synuclein, NfL, GFAP and DaT‑SPECT readings. Management said the profile supports additional regulatory engagement to potentially accelerate filing timelines; market reaction lifted shares on the data disclosures. Independent commentators noted that biomarker improvements do not yet prove clinical benefit, and that upcoming clinical endpoint readouts and longer follow‑up will be required to validate disease‑slowing claims.